Clinical Trials on Specific Antibody Deficiency

Total 10800 results

H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Unknown

CP-609,754 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Milton S. Hershey Medical Center

Unknown

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

AFP464 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Institute of Cancer Research, United Kingdom
National Cancer Institute (NCI)

Unknown

17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
National Cancer Institute (NCI)

Completed

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ro 31-7453 in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Cancer Research UK

Completed

Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Dale Shepard, MD, PhD
National Cancer Institute (NCI)

Terminated

Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States, Canada
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Children With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

KRN5500 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Children With Advanced Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
European Organisation for Research and Treatment...

Completed

Mistletoe Lectin in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Unspecified Adult Solid Tumor, Protocol Specific

Germany, France
European Organisation for Research and Treatment...

Suspended

BIBX 1382 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
European Organisation for Research and Treatment...

Withdrawn

CHS 828 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Norway, Switzerland, Netherlands, Belgium, Austria, United Kingdom, Denmark, Germany
European Organisation for Research and Treatment...

Completed

E7070 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of California, Davis
Bristol-Myers Squibb; National Cancer Institute (NCI); Genentech, Inc.

Terminated

Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors (UCDCC#207)

Unspecified Adult Solid Tumor, Protocol Specific

United States
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Proacta, Incorporated

Completed

PR104 and G-CSF in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States, New Zealand
Proacta, Incorporated

Completed

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Completed

Tumor Cell Vaccine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute

Completed

Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Proacta, Incorporated

Completed

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand, United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Amgen

Completed

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Amgen

Completed

A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Japan
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

China
Biola University

Completed

Exploring the Experience of Using a Prayer Mobile App

No Specific Condition. Feasibility of Mobile App

United States
University Hospital, Basel, Switzerland

Completed

Manufacture of Clinical T-cell Products for Future Treatment

Virus-specific T Cells

Switzerland
Roswell Park Cancer Institute
Novartis

Completed

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

Unspecified Adult Solid Tumor, Protocol Specific

United States
Assistance Publique - Hôpitaux de Paris

Withdrawn

Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin By French-speaking Population

The Study Focus on no Specific Condition

France
Assistance Publique - Hôpitaux de Paris

Withdrawn

Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by French-speaking Patients

The Study Focus on no Specific Condition

France
Assistance Publique - Hôpitaux de Paris

Withdrawn

Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin By English-speaking Population

The Study Focus on no Specific Condition

France
Assistance Publique - Hôpitaux de Paris

Withdrawn

Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by French-speaking Population

The Study Focus on no Specific Condition

France
Assistance Publique - Hôpitaux de Paris

Withdrawn

Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by English-speaking Population

The Study Focus on no Specific Condition

France

Clinical Trials on Specific Antibody Deficiency

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations